Equitable Trust Co. Sells 11,792 Shares of Harrow, Inc. $HROW

Equitable Trust Co. reduced its stake in shares of Harrow, Inc. (NASDAQ:HROW) by 21.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 43,243 shares of the company’s stock after selling 11,792 shares during the quarter. Equitable Trust Co. owned about 0.12% of Harrow worth $2,083,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Profund Advisors LLC acquired a new position in Harrow during the 3rd quarter worth $328,000. Oppenheimer & Co. Inc. raised its position in shares of Harrow by 12.6% during the third quarter. Oppenheimer & Co. Inc. now owns 14,994 shares of the company’s stock worth $722,000 after acquiring an additional 1,677 shares during the last quarter. Independent Advisor Alliance bought a new stake in shares of Harrow during the third quarter worth $210,000. AlphaQuest LLC lifted its stake in shares of Harrow by 743.0% during the third quarter. AlphaQuest LLC now owns 3,819 shares of the company’s stock valued at $184,000 after acquiring an additional 3,366 shares during the period. Finally, Great Lakes Advisors LLC boosted its holdings in Harrow by 4.0% in the third quarter. Great Lakes Advisors LLC now owns 26,963 shares of the company’s stock valued at $1,299,000 after acquiring an additional 1,035 shares during the last quarter. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Stock Performance

Shares of NASDAQ:HROW opened at $51.55 on Tuesday. The firm’s 50 day simple moving average is $47.85 and its 200 day simple moving average is $43.17. Harrow, Inc. has a fifty-two week low of $20.85 and a fifty-two week high of $54.85. The company has a market capitalization of $1.91 billion, a price-to-earnings ratio of -515.45 and a beta of 0.07. The company has a debt-to-equity ratio of 5.21, a current ratio of 2.72 and a quick ratio of 2.52.

Analyst Upgrades and Downgrades

HROW has been the subject of several recent research reports. LADENBURG THALM/SH SH boosted their price objective on Harrow from $64.00 to $66.00 and gave the stock a “buy” rating in a report on Wednesday, November 12th. HC Wainwright lifted their price target on shares of Harrow from $64.00 to $69.00 and gave the stock a “buy” rating in a research report on Wednesday, November 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Harrow in a report on Thursday, January 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $94.00 price objective on shares of Harrow in a research note on Tuesday, November 11th. Finally, Zacks Research cut shares of Harrow from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 2nd. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Harrow has an average rating of “Moderate Buy” and an average price target of $71.43.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.